JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
Adjusted earnings exclude intangible amortization expense and special items. Including these items, reported earnings were $2.29 per share, up 18.7% year over year.
Sales of this drug and medical devices giant came in at $23.74 billion, which also beat the Zacks Consensus Estimate of $22.80 billion. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.)
Sales rose 5.8% from the year-ago quarter, reflecting an operational increase of 4.6% and a positive currency impact of 1.2%. Organically, excluding the impact of acquisitions/divestitures and currency, sales rose 3.0% on an operational basis.
Second-quarter sales in the domestic market rose 7.8% to $13.54 billion. Excluding the impact of all acquisitions and divestitures on an adjusted operational basis, domestic sales rose 5.0% in the quarter.
International sales rose 3.2% on a reported basis to $10.2 billion, reflecting an operational increase of 0.6% and a positive currency impact of 2.6%. Excluding the impact of all acquisitions and divestitures on an adjusted operational basis, international sales rose 0.4% in the quarter.
J&J's Innovative Medicines Unit Outperforms, MedTech Misses
With the complete separation of the Consumer Health segment into a newly listed company called Kenvue KVUE in 2023, J&J has now become a two-sector company focused on the Pharmaceutical and MedTech fields. KVUE will report its second-quarter results in early August.
J&J's Innovative Medicines segment sales rose 4.9% year over year to $15.2 billion, reflecting a 3.8% operational increase and a positive currency impact of 1.1%. Excluding the impact of all acquisitions and divestitures and currency on an adjusted operational basis, worldwide sales rose 2.4%. Innovative Medicines sales beat the Zacks Consensus Estimate of $14.55 billion as well as our model estimate of $14.50 billion.
Higher sales of key products such as Darzalex, Tremfya and Erleada due to strong market growth and share gains drove the segment's growth. Xarelto and Simponi/Simponi Aria sales also rose in the quarter. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato contributed significantly to growth. The sales growth was partially dampened by lower sales of Imbruvica and generic/biosimilar competition to drugs like Stelara and Zytiga.
JNJ's Oncology Drugs' Performance
Sales of blockbuster multiple myeloma medicine Darzalex rose 23.0% year over year to $3.54 billion in the quarter. Sales beat the Zacks Consensus Estimate of $3.45 billion and our model estimate of $3.44 billion.
Imbruvica sales declined 4.5% to $735.0 million. Rising competitive pressure in the United States due to new oral competition has been hurting Imbruvica's sales for the past few quarters. Imbruvica sales were, however, better than the Zacks Consensus Estimate of $697.0 million and our estimate of $694.8 million.
Erleada generated sales of $908.0 million in the quarter, up 23.4% year over year. Erleada sales beat the Zacks Consensus Estimate of $853.0 million as well as our model estimate of $903.9 million.
New drug Carvykti recorded sales of $439.0 million compared with $369 million in the previous quarter.Another new drug, Tecvayli, recorded sales of $166.0 million in the quarter, up 23.1% year over year,
Sales of Talvey were $106 million, up 55.0% year over year. Rybrevant/Lazcluze sales were $179 million compared with $69 million in the year-ago quarter.
Zytiga sales declined 11.6% to $145.0 million in the quarter due to generic competition.
JNJ's Immunology Drugs' Performance
Sales of the blockbuster psoriasis drug, Stelara, declined 42.7% to $1.65 billion in the quarterdue to the impact of biosimilar competition and Part D redesign. While U.S. sales of Stelara declined 41.9%, international sales declined 44.2% in the quarter. Stelara sales missed the Zacks Consensus Estimate as well as our model estimates of $1.88 billion.
Several biosimilar versions of J&J's multi-billion-dollar immunology drug, Stelara, have been launched in the United States in 2025. According to patent settlements and license agreements, Amgen AMGN, Teva Pharmaceutical Industries TEVA, Samsung Bioepis/Sandoz and some other companies have already launched Stelara biosimilars this year.
Tremfya recorded sales of $1.19 billion in the quarter, up 31.0% year over year. Tremfya sales beat the Zacks Consensus Estimate of $1.08 billion as well as our model estimate of $1.09 billion.
Simponi/Simponi Aria sales rose 28.6% to $690.0 million. Sales of Remicade rose 15.9% in the quarter to $455.0 million.
JNJ's Neuroscience, PAH and Other Drugs' Performance
In neuroscience, Spravato recorded sales of $414.0 million, up 53.3% year over year. Caplyta, added from the Apil acquisition of Intra-Cellular Therapies, recorded sales of $211 million in the quarter. Invega Sustenna/Xeplion/Invega Trinza/Trevicta sales declined 5.9% to $992.0 million in the quarter.
Pulmonary arterial hypertension (PAH) drug Uptravi recorded sales of $476.0 million, up 11.7% year over year. Another PAH drug, Opsumit, recorded sales of $582.0 million, up 6.4% year over year.
Xarelto sales rose 5.6% in the quarter to $621.0 million. Prezista sales declined 9.4% to $396.0 million.
How Did JNJ's MedTech Segment Perform in Q2?
MedTech segment sales came in at $8.54 billion, up 7.3% from the year-ago period, including an operational increase of 6.1% and a positive currency impact of 1.2%. MedTech segment sales beat the Zacks Consensus Estimate of $8.25 billion as well as our model estimate of $8.31 billion.
Excluding the impact of all acquisitions and divestitures, and currency, on an adjusted operational basis, worldwide sales rose 4.1%.
In the MedTech segment, over the past couple of quarters, gains from recent acquisitions of Shockwave and Abiomed, as well as continued uptake of new products, have been offset by continued headwinds in Asia Pacific, specifically in China and increased competitive pressure in U.S. electrophysiology for PFA ablation catheter. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program. VBP is a government-driven cost containment effort in China.
JNJ Ups 2025 Sales and EPS Guidance Range
The company raised its sales expectations for 2025 by around $2.0 billion to reflect a strong operational performance coupled with currency tailwinds.
The sales guidance was raised from a range of $91.0 billion-$91.8 billion to $93.2 billion-$93.4 billion.
The sales range indicates growth in the range of 5.1%-5.6% versus the prior expectation of 2.6%-3.6%. Operational sales growth is expected in the range of 4.5%-5.0% (previously 3.3%-4.3%).
Adjusted operational sales (excluding currency impact, acquisitions/divestitures) growth is expected in the range of 3.2%-3.7% (previously 2.0%-3.0%).
The revenue figures exclude revenues from COVID-19 vaccine sales.
The adjusted earnings per share guidance was raised from a range of $10.50-$10.70 to $10.80-$10.90. On an operational, constant-currency basis, adjusted earnings per share are expected to increase in the range of 8.2%-9.2% (previously 5.2% to 7.2%).
Our Take on JNJ's Q2 Results
J&J kicked off the earnings season for the drug and biotech sector with earnings and sales beats. Despite the loss of exclusivity ('LOE') of Stelara, its Innovative Medicines unit once again outperformed expectations, with sales of all key drugs Darzalex, Erleada and Tremfya beating estimates. The new drugs also contributed significantly to sales. Stelara LOE hurt revenue growth by 1170 basis points in the second quarter.
MedTech unit's sales also beat estimates. J&J raised its sales and EPS guidance for the year. J&J's shares rose more than 2% in pre-market trading on Wednesday in response to the earnings beat and guidance raise.
So far this year, J&J's stock has risen 9.1% compared with an increase of 1.9% for the industry.
Image Source: Zacks Investment Research
J&J's Innovative Medicine unit is showing a growth trend. In 2025, J&J expects growth in the Innovative Medicine segment in the face of Stelara biosimilar entrants to be driven by its key products such as Darzalex, Tremfya, Spravato and Erleada, as well as new drugs like Carvykti, Tecvayli and Talvey, and new indications for Tremfya and Rybrevant.
J&J considers 2025 to be a 'catalyst year,' positioning the company for growth in the second half of the decade. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half of the year than in the first. While newly launched products should drive growth in the Innovative Medicines segment in the second half, the MedTech segment may benefit from new products and easier comps.
J&J is also making rapid progress with its pipeline and has been on an acquisition spree lately, which has strengthened its pipeline.
However, the softness in the MedTech unit, the Stelara patent cliff and the potential impact of Part D redesign will be significant headwinds in 2025. It remains to be seen how the company navigates them. The legal battle surrounding its talc lawsuits is a persistent headwind.
J&J's Zacks Rank
J&J currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Johnson & Johnson Price, Consensus and EPS Surprise
Johnson & Johnson price-consensus-eps-surprise-chart | Johnson & Johnson Quote
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
Amgen Inc. (AMGN) : Free Stock Analysis Report
Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report
Kenvue Inc. (KVUE) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Johnson & Johnson (JNJ)'s Pasritamig Shows Breakthrough Promise in Prostate Cancer
We recently published Johnson & Johnson stands second among the most undervalued stocks. Johnson & Johnson (NYSE:JNJ) is a global healthcare leader with a diverse portfolio across pharmaceuticals, medical devices, and consumer health. Its Innovative Medicine division focuses on treatments for complex diseases, while MedTech develops minimally invasive solutions in cardiovascular, orthopedic, surgical, and vision care. In June 2025, Johnson & Johnson (NYSE:JNJ) reported promising Phase 1 results for pasritamig (JNJ-78278343), a first-in-class bispecific T-cell-engaging antibody for metastatic castration-resistant prostate cancer (mCRPC). The drug targets KLK2, a prostate cancer-specific biomarker, and showed early antitumor activity with low treatment-related side effects, indicating potential for safe outpatient use. Pixabay/Public Domain Other notable advances include a supplemental FDA application for STELARA to treat pediatric Crohn's disease, and early Phase 1b data showing encouraging responses from bleximenib—a menin inhibitor—combined with venetoclax and azacitidine for genetically defined acute myeloid leukemia (AML). In vision care, the company launched the first daily disposable multifocal toric contact lens for astigmatism: ACUVUE OASYS MAX 1-Day MULTIFOCAL. Strategically, Johnson & Johnson (NYSE:JNJ) plans to invest $55 billion over four years to expand U.S.-based manufacturing and R&D, aligning with efforts to boost domestic production and supply chain resilience. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
What is umbrella insurance, and why should you consider it?
Accidents happen. Someone can slip on ice on the walkway to your house and break several bones. You could rear-end the car in front of you on a rainy night. Your dog could bite the mail carrier. Your home or auto insurance can cover the costs of these accidents if you're on the hook for them. Sometimes, though, costs can exceed what your insurance will cover. Then you're at risk of having to pay out of pocket — that is, unless you have an umbrella policy. This embedded content is not available in your region. Learn more: How does car insurance work? The basics explained. Umbrella insurance: 'Often overlooked' 'Umbrella coverage is the often-overlooked safety net that can protect you from financial disaster,' said Jason Javaheri, co-founder and CEO of Los Angeles-based J&Y Law Firm, which represents injury victims. And the cost is relatively low for the protection it provides. J.D. Power's Craig Martin said that according to the J.D. Power 2024 U.S. Homeowners Insurance Study, only 38% of customers with an annual income over $200,000 indicated they have an umbrella policy, while only 22% of those with incomes between $100,000 and $200,000 had an umbrella policy. The percentage dropped to 14% for those with incomes less than $100,000. That's why it pays to understand what an umbrella policy is, how it works, what it covers, and how much coverage you might need. Learn more: Homeowners insurance: What it covers and how much you'll pay What is an umbrella policy? An umbrella policy is a type of insurance that provides additional coverage if you exceed the liability limits on your home, auto, or other property insurance. It's meant to protect your assets if there is a large claim or judgment against you. Standard homeowners and auto insurance policies typically provide liability coverage for costs such as medical bills and legal fees if you're responsible for causing property damage or injuries to others — but only up to certain limits. You could easily top those limits if, for example, you were sued for damages related to a multi-vehicle car accident with several injuries. 'That's where umbrella would come into place,' said Kim Bowser, vice president of national product and experience development at Grange Insurance. 'Your auto or home insurance would typically cover the loss first. Umbrella kicks in as an extra layer on top of that coverage protection.' Up next Up next How an umbrella policy works Umbrella policies are available in million-dollar increments, ranging from $1 million to $5 million (but potentially higher for high-net-worth individuals and families), explained Erika Tortorici, owner and principal of Optimum Insurance Solutions in Hamilton, Massachusetts. To buy a policy, you must already have a certain amount of liability coverage through auto, home, or other property insurance. Insurers typically require a minimum of $300,000 in liability coverage on a homeowners policy and $250,000 per person/$500,000 per accident liability coverage on an auto policy. Learn more: How much car insurance do I need? Those thresholds are high because umbrella insurance is meant to cover only large claims, said Jennifer Gambill, a Miami-based independent insurance broker with World Insurance Associates. For example, if you were sued because someone was injured on your property and had to pay $500,000, your home insurance would pay up to its $300,000 limit, then an umbrella policy would pay the remaining $200,000. What does umbrella insurance cover? An umbrella policy provides coverage for both your home and your automobiles. It can also be extended to cover recreational vehicles, boats and other watercraft, rental property and timeshares, and other members of your household, including children away at school, Gambill said. An umbrella policy provides coverage for the following: Injuries to others, including the cost of medical bills and liability claims Damage to other people's property Personal injury to others, including libel, slander, and defamation Your legal fees to defend yourself in a lawsuit Learn more: What does homeowner insurance cover? What will an umbrella policy not cover? An umbrella policy covers your liability to others, not damages or injuries to you or your property. 'If your dog were to bite you, the umbrella policy typically wouldn't cover those medical costs you might incur,' Bowser said. It also does not provide coverage for the following: Intentional injuries to others Illegal activities, including accidents and injuries related to drag racing Losses related to a business you run out of your home Legal costs related to something you agreed to in a contract What types of claims would fall under an umbrella policy? Here are just a few examples of the types of claims that would be covered under an umbrella policy. You accidentally hit someone while driving or cause a serious accident with multiple vehicles You post something defamatory about someone on social media and are sued Your children's friends are injured on your trampoline or pool Your dog seriously injures a delivery person Learn more: What does homeownership not cover? This embedded content is not available in your region. How much umbrella coverage do you need? The amount of umbrella coverage you need depends on what you want to protect. For a standard two-car household with one home, $1 million in umbrella coverage can be adequate, said Alaina Hixson, director of sales and operations at The Churchill Agency, an independent insurance agency near Nashville, Tennessee. 'The more assets you have, the more protection you need,' she said. You might also need more protection if you are exposed to more risks, such as teen drivers in your household or a sport or hobby such as hunting that could result in others being injured. Your insurance agent can help you assess how much umbrella coverage you need. How much does umbrella insurance cost? Umbrella insurance is relatively inexpensive for the coverage you get, said Tortorici. For example, a household with one home and two drivers would typically pay $250 to $350 a year for a $1 million umbrella policy, she added. Adding teen drivers to your coverage will drive up your rates. So will multiple properties, vehicles, and watercraft. Your location, claims history, and driving record will also affect the cost of umbrella insurance. However, you typically can get a multi-policy discount when bundling an umbrella policy with your existing home, auto, or other property insurance. Learn more: How much is homeowners insurance? A guide to lowering costs. Pros and cons of an umbrella policy There are plenty of benefits of owning an umbrella policy, but there are a few cons to consider. Pros Expanded liability coverage to protect your assets if your underlying home or auto insurance liability coverage isn't enough to pay for large claims Relatively low cost for the coverage you get Wide range of coverage for liability claims Additional coverage for claims not typically covered by home and auto insurance, such as libel, slander, and even false arrest Coverage for other household members in addition to coverage for the policyholder A single policy can cover a range of property, including a home, vehicles, and watercraft Cons High underlying liability limits on your home and auto insurance are required to purchase umbrella coverage Coverage is limited to injuries and damage to others and their property, not you or your property Additional cost of owning a supplemental insurance policy Who needs umbrella insurance? 'Umbrella insurance isn't just for the wealthy,' Javaheri said. 'It is for anyone with something to protect.' You should consider an umbrella policy if any of the following applies to you: You own a home and vehicles You own rental property You have a high net worth You have teen drivers You have a pool or trampoline You have an RV, boat, or other watercraft You have a dog You engage in high-risk activities that could injure someone else Who doesn't need umbrella insurance? To have umbrella insurance, you must have certain primary insurance protection in place. 'If you don't own a car or home, you can't get an umbrella policy,' Gambill explained. For example, you probably don't need umbrella insurance if you are a renter who relies on public transportation. That said, you still should get renters insurance with the maximum amount of liability coverage available. Learn more: How an auto and renters insurance bundle can save you big How to get an umbrella policy The best way to get an umbrella policy is through your existing auto or home insurance provider. In fact, if you want an umbrella policy to cover your home, vehicle, and other property, all policies have to be under the same insurance carrier, Hixson said. Plus, having multiple policies with one carrier usually allows you to score a discount on your premiums. Rarely would it make sense to get an umbrella policy through a different insurance carrier than the one you have. A few circumstances, such as owning a hard-to-insure breed of dog or having a bad driving record, might force you to get an umbrella policy through a specialty carrier, Tortorici said. Umbrella insurance FAQs What are the disadvantages of an umbrella policy? You can't buy an umbrella policy unless you already have an auto or homeowners policy with a high level of liability coverage. You might have to switch insurers if your current provider of home or auto insurance doesn't offer umbrella coverage. Plus, an umbrella policy is an additional insurance cost. 'You're paying for the peace of mind,' Tortorici said. 'Hopefully, you don't use your umbrella.' Is umbrella insurance worth it? Umbrella insurance can protect your assets if you accidentally injure someone or damage property and have to pay a large claim. Although most state laws prevent your home from being seized if you're sued, your other property, investments, and wages could be at risk if you don't have enough liability coverage through your existing home or auto insurance to pay claims. 'I've seen [umbrella insurance] do amazing things to help people,' Hixon said. 'I don't think you can be overprotected when it comes to liability in this country.' Do I have to get umbrella insurance through my current provider? You usually have to buy umbrella insurance through the insurance company that provides your auto or home insurance. However, some insurance companies offer stand-alone umbrella policies, meaning you don't have an auto or homeowners policy with them. Tim Manni edited this article.
Yahoo
10 hours ago
- Yahoo
Are Investors Undervaluing Kion Group (KIGRY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large. Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now. One company value investors might notice is Kion Group (KIGRY). KIGRY is currently sporting a Zacks Rank #2 (Buy) and an A for Value. The stock is trading with P/E ratio of 17.3 right now. For comparison, its industry sports an average P/E of 29.01. Over the past 52 weeks, KIGRY's Forward P/E has been as high as 18.76 and as low as 9.39, with a median of 11.61. Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. KIGRY has a P/S ratio of 0.64. This compares to its industry's average P/S of 1.22. These figures are just a handful of the metrics value investors tend to look at, but they help show that Kion Group is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, KIGRY feels like a great value stock at the moment. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Kion Group (KIGRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
